The shares of Gilead Sciences Inc. (NASDAQ:GILD) has been pegged with a rating of Overweight by Piper Sandler in its latest research note that was published on March 20, 2020. The Healthcare company has also assigned a $90 price target. Piper Sandler wasn’t the only research firm that published a report of Gilead Sciences Inc., with other equities research analysts also giving their opinion on the stock. DZ Bank advised investors in its research note published on March 18, 2020, to Buy the GILD stock while also putting a $80 price target. The stock had earned Outperform rating from RBC Capital Mkts Markets when it published its report on March 09, 2020. That day the RBC Capital Mkts set price target on the stock to $86. The stock was given Underweight rating by Barclays in its report released on February 27, 2020, the day when the price target on the stock was placed at 62. Bernstein was of a view that GILD is Mkt Perform in its latest report on February 06, 2020. Raymond James thinks that GILD is worth Outperform rating. This was contained in the firm’s report on February 05, 2020 in which the stock’s price target was also moved to 80.
Amongst the analysts that rated the stock, 3 have recommended investors to sell it, 11 believe it has the potential for further growth, thus rating it as Hold while 11 advised investors to purchase the stock. The price of the stock the last time has raised by 14.40% from its 52-Week high price while it is -18.97% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 46.65.
The shares of the company dipped by -5.81% during the trading session on Wednesday, reaching a low of $69.34 while ending the day at $69.66. During the trading session, a total of 23.01 million shares were traded which represents a -21.24% decline from the average session volume which is 18.98 million shares. GILD had ended its last session trading at $73.96. Gilead Sciences Inc. currently has a market cap of $89.0 billion, while its P/E ratio stands at 16.55, while its P/E earnings growth sits at 64.41, with a beta of 0.40. Gilead Sciences Inc. debt-to-equity ratio currently stands at 1.09, while its quick ratio hovers at 3.00 GILD 52-week low price stands at $60.89 while its 52-week high price is $85.97.
The company in its last quarterly report recorded $1.10 earnings per share which is below the predicted by most analysts. The Gilead Sciences Inc. generated 11.63 billion in revenue during the last quarter. In the second quarter last year, the firm recorded $1.65 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -51.82%. Gilead Sciences Inc. has the potential to record 6.03 EPS for the current fiscal year, according to equities analysts.
Even though the stock has been trading at $21.65/share, analysts expect it to surge by 7.81% to reach $51.50/share. It started the day trading at $24.54 and traded between $21.26 and $23.34 throughout the trading session.
A look at its technical shows that FOX’s 50-day SMA is 32.40 while its 200-day SMA stands at 33.83. The stock has a high of $38.91 for the year while the low is $19.13. The stock, however, witnessed a rise in its short on 03/13/20. Compared to previous close which recorded 2.53 M shorted shares, the short percentage went higher by 21.35%, as 3.07M GILD shares were shorted. At the moment, only 0.54% of Fox Corporation shares were sold short. The company’s P/E ratio currently sits at 8.17, while the P/B ratio is 1.38. The company’s average trading volume currently stands at 1.88M shares, which means that the short-interest ratio is just 1.35 days. Over the past seven days, the company moved, with its shift of 9.01%. Looking further, the stock has dropped -36.28% over the past 90 days while it lost -25.98% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The T. Rowe Price Associates, Inc. (I… bought more FOX shares, increasing its portfolio by 2.52% during the last quarter. This move now sees The T. Rowe Price Associates, Inc. (I… purchasing 423,154 shares in the last quarter, thus it now holds 17,223,839 shares of FOX, with a total valuation of $524,465,898. The Vanguard Group, Inc. meanwhile sold more FOX shares in the recently filed quarter, changing its stake to $368,408,003 worth of shares.
Similarly, BlackRock Fund Advisors increased its Fox Corporation shares by 1.60% during the recently filed quarter. After buying 8,698,251 shares in the last quarter, the firm now controls 137,063 shares of Fox Corporation which are valued at $264,861,743. In the same vein, Yacktman Asset Management LP increased its Fox Corporation shares by during the most recent reported quarter. The firm bought 656,684 shares during the quarter which increased its stakes to 8,379,718 shares and is now valued at $255,162,413. Following these latest developments, around 38.95% of Fox Corporation stocks are owned by institutional investors and hedge funds.